News
The coolest brand in hot flash relief: behind Femography’s menopause clothing revolution
In an era when menopause was seldom addressed, Femography courageously launched Become
In the realm of women’s health, an exciting revolution is underway, and at its forefront is Femography, a trailblazing brand in the femtech industry.
Backed by a formidable apparel conglomerate and embraced by women worldwide, Femography is more than just a brand – it’s a movement reshaping the menopause apparel industry. This feature dives into Femography’s journey and highlights a ‘cool’ gift idea for your friends and loved ones – figuratively and literally.
Powered by an apparel giant: a leap in women’s health
Femography distinguishes itself in the femtech space with the robust backing of MAS Holdings, a titan in South Asia’s apparel tech industry. This partnership propels Femography forward in a sector where a mere three per cent of women’s health-focused businesses have secured financing since 2011.
It marks a significant step in filling a gap in women’s health — a crucial but often overlooked area — positioning Femography as a visionary leader.
Scientific breakthrough meets lifestyle
The cornerstone of Femography’s success lies in its groundbreaking patented Anti-Flush™ Technology, ingeniously crafted to tackle the three stages of a hot flash, a predominant symptom of menopause.
This innovation transcends the boundaries of science, offering lifestyle solutions that blend seamlessly into everyday life. It’s this unique fusion of scientific ingenuity and practical utility that sets Femography apart, carving out its niche in the market.
Femography’s holistic product line
Femography’s product development approach is comprehensive and thoughtful. Their expansive product line, including Anti-Flush™ sleepwear, camisoles, panties, loungewear, tank tops, leggings and ultra absorbent underwear, is designed with the utmost care to ease menopause-related discomforts.
Each item in this diverse array is crafted to empower women, enabling them to lead fulfilling lives without the burdens of menopause symptoms.
Enter Become: pioneering change with Femography’s consumer brand
In an era when menopause was seldom addressed, Femography courageously launched Become, its consumer brand dedicated to menopause apparel. This bold initiative has led the way for seven years, transforming societal perceptions and dismantling stigmas around menopause.
Become has not only brought relief to countless women but has also been instrumental in evolving the market, cultivating a space where menopause is openly discussed and managed with dignity and understanding.
A cool gift idea: embrace the holiday spirit with Become
This holiday season, Femography invites you to reimagine gift-giving. Sharing Become’s revolutionary clothing with friends is a wonderful way to support those experiencing menopause. It’s more than a gift; it’s an expression of care, offering real comfort in daily life.
This thoughtful gesture of gifting cooling apparel is not only practical but also a symbol of empathy and unity. And what could be cooler than presenting a gift that brings literal and figurative coolness to someone’s life?
Femography’s broader impact as a leading B2B partner
Femography’s journey in the femtech revolution is marked not just by its technological innovation but also by its deep understanding of consumer needs.
While the holiday season offers a moment to focus on individual gifting, the broader, year-round scope of Femography’s impact lies in its role as a powerful B2B partner in the health and apparel sectors. This dual focus reflects Femography’s commitment to enhancing the lives of individual women and driving forward the industry as a whole.
By offering cutting-edge solutions like their Anti-Flush™ technology, Femography has set new standards in menopause apparel. Their innovative approach extends beyond product development to fostering meaningful collaborations with businesses and brands.
Femography amplifies its impact through these partnerships, making women’s health solutions more accessible and creating a global ripple effect of well-being and empowerment.
Small bowel microbiome differences between women and men may help explain why some conditions are more common in women, a study suggests.
The small bowel microbiome is the community of microorganisms living in this part of the digestive tract, where they play vital roles in immune function, metabolism and hormonal regulation.
Researchers found differences between women and men in the composition and organisation of these microbial communities. One bacterial community containing Granulicatella was found only in women.
The study was conducted by investigators at Cedars-Sinai Health Sciences University.
Ruchi Mathur, director of clinical research and clinical operations for the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai and corresponding author of the study, said: “One intriguing finding was a bacterial community containing Granulicatella, which we found only in women.
“Bacteria in this community appear at increased levels in women with polyendocrine metabolic ovarian syndrome, formerly known as polycystic ovary syndrome.”
The researchers also identified differences between women and men in how microbes in the small bowel produce fructans, complex carbohydrates known to trigger digestive symptoms in irritable bowel syndrome (IBS).
IBS is far more common in women than men.
Mathur, who is also a professor of medicine, said: “Our findings show that biological sex is a critical variable in the small bowel microbiome.
“We must consider it as we move toward more personalised approaches to understanding and treating disease.”
An experimental cancer drug reduced bone loss and body fat in mice modelling post-menopausal changes, early research suggests.
The compound, CADD522, appeared to strengthen bones and help the animals stay leaner after surgery designed to mimic hormonal changes seen after menopause.
The treatment remains at an early experimental stage and has so far only been tested in animals.
The study, led by the University of East Anglia, investigated CADD522, which was originally developed to block a protein involved in the growth and spread of several cancers.
Mice treated with the compound for eight weeks showed significant improvements in bone health. Scans found increased bone volume and better preservation of the honeycomb-like structures inside bones that are crucial for strength and resilience.
Blood tests suggested the treatment stimulated new bone growth without interfering with the body’s normal process of breaking down and rebuilding bone.
Dr Darrell Green, lead researcher from UEA’s Norwich Medical School, said: “Osteoporosis affects around one in three women over the age of 50, leaving sufferers vulnerable to painful fractures that can seriously impact quality of life.
“Current treatments exist, but many are plagued by side effects, safety concerns or inconvenient dosing schedules that make long-term use difficult.”
The researchers also found that mice receiving CADD522 weighed less than untreated mice despite eating the same amount of food.
They had less body fat and fewer fat deposits in their bone marrow, a process commonly seen after menopause and linked to declining bone health.
The team also examined brain tissue and found that the drug appeared to reverse several menopause-related changes in fatty acids.
Levels of omega-3 fats including DHA remained largely intact, while several other lipid abnormalities shifted back towards healthier patterns.
Green said: “We didn’t directly test for memory or thinking ability, but our work raises questions about whether this drug could one day help address wider menopause-related health problems.”
Safety experiments in mice, rats and dogs found that CADD522 could be taken orally and was well tolerated.
The compound also appeared to be metabolised more slowly in human tissue than in rodents, potentially improving its performance in people.
“This is still in the early stages and has so far only been tested in animals but we hope that the benefits will translate to humans to ultimately reduce fracture rates,” added Green.
The research was led by UEA in collaboration with the University of Maryland, the Scintillon Research Institute in San Diego and the University of Stirling.
Safety testing was funded by The Sir William Coxen Trust as part of the development of CADD522 as a childhood cancer treatment.
Weight loss surgery was linked to more regular periods and fewer polyendocrine metabolic ovarian syndrome (PMOS) symptoms in women aged 18 to 45 living with obesity in a recent study.
The researchers recommend that women undergoing the procedure have access to preconception care and reproductive counselling to support their reproductive health.
Researchers at the University of Surrey analysed data over 24 months from 84 women who underwent bariatric surgery and 18 women living with obesity who did not have surgery.
Of those who underwent surgery, 49 had gastric bypass procedures and 35 had gastric sleeve surgery.
Women who underwent metabolic bariatric surgery lost more than 30kg on average at 12 and 24 months after the procedure.
Among women with polycystic ovaries, the condition persisted in only 10 per cent after 24 months.
Women also reported a resolution of clinical hirsutism, or excess body hair, by 12 months.
Women who had previously experienced irregular periods reported more regular menstrual cycles after surgery.
Professor Martin Whyte, co-author of the study and professor of metabolic medicine at the University of Surrey, said: “A large proportion of those undergoing bariatric surgery are women of reproductive age, who may be planning a pregnancy in the coming years.
“So much remains unknown about the impact of this type of surgery on women who are planning to have children.
“This raises the question of when the ideal time after surgery is to conceive.”
Women have a higher prevalence of obesity than men, with 57 per cent of women in the UK classified as overweight and 27 per cent living with obesity, which can affect fertility and the health of an unborn baby.
The researchers said 17 women had healthy pregnancies following surgery.
Although this was not specifically examined in the study, no difference in birth weight was observed between babies conceived within or after the first year.
Dr Kathryn Hart, co-author of the study and associate professor in nutrition and dietetics at the University of Surrey, said: “What we have found is that bariatric surgery positively affects the reproductive health of women living with obesity and can improve the likelihood of them having a healthy pregnancy after surgery.
“Dysregulated hormone levels, irregular periods and conditions such as polycystic ovaries are affected by obesity.
“By reducing this, what we have seen is that it can lead to improvements without the need for medication.
“We would suggest that clinicians consider medical intervention for obesity to treat irregularities in the menstrual cycle and issues with fertility.”
Hormonal health2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur6 days agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Fertility2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Mental health1 week agoUK study aims to transform maternity care for high-risk pregnancies
Menopause2 weeks agoQuarter of women miss work due to menstual symptoms, survey finds
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Menopause4 days agoMenopause hormone treatment may ease brain fog, study suggests
4 Comments